Table 1.
1. Pulmonary arterial hypertension |
1.1 Hdiopathic PAH |
1.2 Heritable PAH |
1.2.1 BMPR2 |
1.2.2 ALK-1, ENG, SMAD9, CAV1, KCNK3 |
1.2.3 Unknown |
1.3 Drug and toxin induced |
1.4 Associated with: |
1.4.1 Connective tissue disease |
1.4.2 HIV infection |
1.4.3 Portal hypertension |
1.4.4 Congenital heart diseases |
1.4.5 Schistosomiasis |
1’ Pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis |
1” Persistent pulmonary hypertension of the newborn (PPHN) |
2. Pulmonary hypertension due to left heart disease |
2.1 Left ventricular systolic dysfunction |
2.2 Left ventricular diastolic dysfunction |
2.3 Valvular disease |
2.4 Congenital/acquired left heart inflow/outflow tract obstruction and congenital cardiomyopathies |
3. Pulmonary hypertension due to lung diseases and/or hypoxia |
3.1 Chronic obstructive pulmonary disease |
3.2 Interstitial lung disease |
3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern |
3.4 Sleep-disordered breathing |
3.5 Alveolar hypoventilation disorders |
3.6 Chronic exposure to high altitude |
3.7 Developmental lung diseases |
4. Chronic thromboembolic pulmonary hypertension (CTEPH) |
5. Pulmonary hypertension with unclear multifactorial mechanisms |
5.1 Hematologic disorders: chronic hemolytic anemia, myeloproliferative disorders, splenectomy |
5.2 Systemic disorders: sarcoidosis, pulmonary histiocytosis, lymphangioleiomyomatosis |
5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders |
5.4 Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure, segmental PH |
[83]Adapted from Simmonneau JACC 2013;62(25 Suppl):D34–41.